Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Urologic oncology

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2012.01.012PMID 23218068PMCID PMC3524835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results.

  2012cited by this paper
• Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.

  2012cited by this paper
• Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

  2012cited by this paper
• International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

  2011influential reference
• Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy

  2011cited by this paper
• Can we reliably identify patients for radical cystectomy without neoadjuvant chemotherapy?

  2011cited by this paper
• Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

  2011cited by this paper
• Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I.

  2011cited by this paper
• Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer.

  2011cited by this paper
• Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

  2010cited by this paper
• Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.

  2009cited by this paper
• Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

  2009cited by this paper
• Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder

  2009cited by this paper
• A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

  2009cited by this paper
• Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

  2009cited by this paper
• A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder

  2008cited by this paper
• Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial

  2008cited by this paper
• Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.

  2008cited by this paper
• Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

  2007cited by this paper
• Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer.

  2007cited by this paper
• Standardization of pelvic lymphadenectomy performed at radical cystectomy

  2006cited by this paper
• Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.

  2006cited by this paper
• Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder

  2006cited by this paper
• Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

  2006cited by this paper
• Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

  2005cited by this paper
• Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

  2005cited by this paper
• Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma

  2005cited by this paper
• Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

  2004cited by this paper
• A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer

  2004cited by this paper
• Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors.

  2004cited by this paper
• Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base.

  2003cited by this paper
• Can patient selection for bladder preservation be based on response to chemotherapy?

  2003cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003influential reference
• Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?

  2003cited by this paper
• Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

  2003cited by this paper
• Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.

  2003cited by this paper
• Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy.

  2003cited by this paper
• Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.

  2003cited by this paper
• Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

  2002cited by this paper
• Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

  2001cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder.

  2001cited by this paper
• Cystectomy for bladder cancer: a contemporary series.

  2001cited by this paper
• The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.

  2000cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

  2000cited by this paper
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

  1999cited by this paper
• Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort.

  1999cited by this paper
• A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder.

  1999cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases.

  1997cited by this paper
• Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

  1997cited by this paper
• Uncertainty and outcome of invasive bladder tumors.

  1996cited by this paper
• A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

  1996cited by this paper
• Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study

  1996cited by this paper
• Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.

  1995cited by this paper
• Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial.

  1994cited by this paper
• Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

  1994cited by this paper
• The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.

  1992cited by this paper
• Will Rogers and the results of radical cystectomy for invasive bladder cancer.

  1991cited by this paper
• Will Rogers and the results of radical cystectomy for invasive bladder cancer.

  1991cited by this paper
• Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification.

  1991cited by this paper
• Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer.

  1990cited by this paper
• Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group.

  1989cited by this paper

• Kidney function improvement after urinary diversion for cisplatin eligibility in bladder cancer patients

  2025cites this paper
• A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer.

  2022cites this paper
• Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer

  2022cites this paper
• Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy

  2022cites this paper
• Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.

  2022cites this paper
• Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013

  2021cites this paper
• Use of treatment pathway improves neoadjuvant chemotherapy use in muscle-invasive bladder cancer

  2021cites this paper
• Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in “High-Risk” Patients Following Radical Cystectomy: A Retrospective Cohort Study

  2021cites this paper
• Trends of Muscle Invasive Bladder Cancer: Evidence from the SEER Database, 1988 to 2013

  2020cites this paper
• Prognosis of patients receiving induction chemotherapy for locally advanced or lymph node metastatic bladder cancer

  2020cites this paper
• Techniques and Outcomes of Taeniamyoectomyised Sigmoid Neobladder in MIS Radical Cystectomy

  2019cites this paper
• Treatment of musculo-invasive bladder cancer with poor prognosis: urgency of the problem

  2018cites this paper
• Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.

  2018cites this paper
• Prognostic Value of Testing PD‐L1 Expression After Radical Cystectomy in High‐risk Patients

  2018cites this paper
• Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.

  2018cites this paper
• Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism

  2018cites this paper
• Anti–Programmed Cell Death 1/Ligand 1 (PD‐1/PD‐L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development

  2017cites this paper
• Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

  2017cites this paper
• Contemporary update on neoadjuvant therapy for bladder cancer

  2017cites this paper
• Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study

  2016cites this paper
• A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy

  2016cites this paper
• Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells.

  2016cites this paper
• Adjuvant chemotherapy for invasive bladder cancer

  2015cites this paper
• Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer

  2015cites this paper
• New and promising strategies in the management of bladder cancer.

  2015cites this paper
• Clinical Scenario: Large Volume, Non-metastatic T2 Bladder Tumor

  2015cites this paper
• A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.

  2015cites this paper
• Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

  2015cites this paper
• Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity

  2014cites this paper
• A Retrospective Analysis of Incidence and Its Associated Risk Factors of Upper Urinary Tract Recurrence following Radical Cystectomy for Bladder Cancer with Transitional Cell Carcinoma: The Significance of Local Pelvic Recurrence and Positive Lymph Node

  2014cites this paper
• Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review

  2014cites this paper
• The future of bladder cancer care in the USA

  2014cites this paper
• Multimodal management of muscle-invasive bladder cancer.

  2014influential citation
• Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

  2014cites this paper
• Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

  2014cites this paper
• 394 CONCORDANCE IN MOLECULAR MARKER STATUS BETWEEN BLADDER TUMORS AT TIME OF TRANSURETHRAL RESECTION AND SUBSEQUENT RADICAL CYSTECTOMY: RESULTS OF A 5-YEAR PROSPECTIVE STUDY

  2013cites this paper
• [Clinical guidelines for diagnosing, treatment and monitoring patients with bladder cancer--Croatian Oncology Society and Croatian Urology Society, Croatian Medical Association].

  2013cites this paper
• Muskelinvasives Harnblasenkarzinom nach radikaler Zystektomie

  2013cites this paper